Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 1, 2023.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter and first nine months of 2023.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2023.

Quest Diagnostics Inc (DGX, Financial), a leading provider of diagnostic information services, released its Q3 2023 earnings report on October 24, 2023. Despite a decrease in overall revenues, the company's base business revenues showed growth, largely due to strength in their physician and hospital channels.

On October 24, 2023, Danaher Corp (DHR, Financial) released its Q3 2023 earnings report, revealing a net earnings of $1.1 billion, or $1.51 per diluted common share.

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023.

BioMérieux reported on Friday that its second quarter 2023 revenues increased 5 percent driven by strong momentum in microbiology, its BioFire non-respiratory panel, and industrial applications.

VC investment in medtech fell across 2022, and the downward trend in deal value continued in the first quarter of 2023. The second quarter brought potential signs that a recovery is starting. Deal value ticked up from $2.5 billion to $2.8 billion between the first and second quarters, and the number of deals rose from 183 to 189.